GSK (NYSE:GSK) Trading Up 6.9% - Still a Buy?

Key Points

• GSK shares jumped 6.9% to about $55.58 after second-quarter adjusted earnings and revenue exceeded expectations, with vaccines contributing to the stronger performance.
• Management raised its FY 2026 adjusted EPS outlook to $4.90–$5.00 and announced a cost-saving plan targeting $2.52 billion in annual savings by 2029, supported by positive oncology pipeline news.
• Risks remain, including revenue guidance below consensus, a planned R&D relocation affecting roughly 1,800 employees, and a mostly neutral analyst stance; MarketBeat lists an average rating of Hold with a $53 consensus target.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) shares rose 6.9% during trading on Tuesday . The stock traded as high as $55.62 and last traded at $55.5750. 1,685,655 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 4,652,362 shares. The stock had previously closed at $51.98.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Second-quarter results beat expectations. Adjusted earnings were $1.36 per share, above the $1.27 consensus and up from $1.23 a year earlier. Revenue rose roughly 5% to £8.41 billion, exceeding forecasts, with vaccines helping drive the performance. GSK Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: GSK raised its FY 2026 adjusted EPS outlook to $4.90-$5.00, above the $4.79 analyst consensus. The improved profit outlook supports investor confidence in the company’s earnings momentum. GSK Hits Three-Month High as Vaccines Help Earnings Top Forecasts
• Positive Sentiment: A new cost-saving plan targets $2.52 billion in annual savings by 2029. Management intends to redirect resources toward faster development of medicines and its longer-term 2031 sales objectives. GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
• Positive Sentiment: Pipeline news added support: partner Hansoh Pharmaceutical’s experimental cancer drug Ris-Rez met the primary goal in a late-stage bone-cancer trial, strengthening the potential value of GSK’s oncology collaboration. GSK, Hansoh’s Cancer Drug Meets Main Goal of Bone Cancer Trial
• Neutral Sentiment: GSK plans to invest £400 million in Britain over three years, including a new Cambridge R&D center. The investment may improve innovation, although it is also restructuring its research footprint. GSK to Invest £400 Million in Britain
• Negative Sentiment: FY 2026 revenue guidance of approximately $44.8 billion is below the $45.7 billion consensus. Additionally, reported EPS was $0.67, below consensus, although adjusted results were stronger; the discrepancy could create uncertainty around earnings quality.
• Negative Sentiment: Closing the Stevenage R&D hub and relocating operations to Cambridge will affect about 1,800 employees, creating execution, restructuring and near-term cost risks.

Analysts Set New Price Targets

Several analysts recently weighed in on GSK shares. HSBC upgraded GSK from a "reduce" rating to a "hold" rating in a report on Monday, July 6th. Weiss Ratings downgraded shares of GSK from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of GSK in a report on Thursday, July 9th. Jefferies Financial Group upgraded shares of GSK to a "strong-buy" rating in a report on Friday, July 17th. Finally, Citigroup started coverage on shares of GSK in a research note on Friday. They issued a "neutral" rating for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $53.00.

GSK Trading Up 3.4%

The stock's 50-day moving average price is $51.62 and its 200 day moving average price is $53.43. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The firm has a market capitalization of $108.73 billion, a PE ratio of 13.97, a price-to-earnings-growth ratio of 3.27 and a beta of 0.35.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Friday, May 15th were issued a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 3.3%. The ex-dividend date was Friday, May 15th. GSK's dividend payout ratio (DPR) is presently 46.49%.

Institutional Investors Weigh In On GSK

Hedge funds have recently made changes to their positions in the company. First Horizon Corp increased its stake in shares of GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company's stock valued at $26,000 after buying an additional 236 shares during the period. Elyxium Wealth LLC bought a new position in GSK during the 4th quarter worth about $30,000. Triumph Capital Management purchased a new position in GSK during the 3rd quarter valued at about $40,000. Coston McIsaac & Partners raised its holdings in shares of GSK by 17.3% in the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company's stock valued at $68,000 after purchasing an additional 206 shares in the last quarter. Finally, Bogart Wealth LLC raised its holdings in shares of GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock valued at $83,000 after purchasing an additional 200 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.